An evaluation of deferiprone as twice-a-day tablets or in combination therapy for the treatment of transfusional iron overload in thalassemia syndromes

References

• Reddy PS, Locke M, Badawy SM. A systematic review of adherence to iron chelation therapy among children and adolescents with thalassemia. Ann Med. 2022 Dec;54(1):326–342.
   PubMed Web of Science ®Google Scholar
• Badawy SM, Thompson AA. Nonmalignant hematology. Cham:Springer;2016. Management of Thalassemias.
   Google Scholar
• Bajwa H, Basit HT. StatPearls. St. Petersburg, Florida: Treasure Island (FL); 2022.
   Google Scholar
• Standards of care guidelines for thalassemia: children’s hospital and research Center Oakland; 2012. [cited 2022 Sep 01]. Available from: https://thalassemia.com/documents/SOCGuidelines2012.pdf
   Google Scholar
• Nezhad FH, Nezhad KH, Choghakabodi PM, et al. Prevalence and genetic analysis of alpha- and beta-thalassemia and sickle cell anemia in Southwest Iran. J Epidemiol Glob Health. 2018 Dec;8(3–4):189–195.
   PubMed Web of Science ®Google Scholar
• Choudhry VP. Thalassemia minor and major: current management. Indian J Pediatr. 2017 Aug;84(8):607–611.
   PubMed Web of Science ®Google Scholar
• Galanello R, Origa R. Beta-thalassemia. Orphanet J Rare Dis. 2010 May 21;5:11.
   PubMed Web of Science ®Google Scholar
• Ali S, Mumtaz S, Shakir HA, et al. Current status of beta-thalassemia and its treatment strategies. Mol Genet Genomic Med. 2021 Dec;9(12):e1788.
   PubMed Web of Science ®Google Scholar
• Gaziev J, Marziali M, Isgro A, et al. Bone marrow transplantation for thalassemia from alternative related donors: improved outcomes with a new approach. Blood. [2013 Oct 10];122(15):2751–2756.
   PubMed Web of Science ®Google Scholar
• FDA advisory committee unanimously supports beti-cel gene therapy for people with beta-thalassemia who require regular red blood cell transfusions: bluebird bio, Inc.; 2022. [cited 2022 Oct 01]. Available from: https://investor.bluebirdbio.com/news-releases/news-release-details/fda-advisory-committee-unanimously-supports-beti-cel-gene
   Google Scholar
• Bluebird bio announces FDA Approval of ZYNTEGLO®, the first gene therapy for people with beta-thalassemia who require regular red blood cell transfusions: bluebird bio, Inc.; 2022 [cited 2022 Oct 10]. Available from: https://investor.bluebirdbio.com/news-releases/news-release-details/bluebird-bio-announces-fda-approval-zynteglor-first-gene-therapy
   Google Scholar
• Vertex and CRISPR therapeutics present new data on more patients with longer follow-up treated with exagamglogene autotemcel (exa-cel) at the 2022 European hematology association (EHA) Congress: Vertex; 2022 [cited 2022 Aug 21]. Available from 2022 Aug 21: https://investors.vrtx.com/news-releases/news-release-details/vertex-and-crispr-therapeutics-present-new-data-more-patients
   Google Scholar
• Portero L Vertex & CRISPR therapeutics’ new data on exa-cel keeps could be first CRISPR-based treatment: urbanhealthtoday; 2022 [cited 2022 Sep 15]. Available from: https://www.docwirenews.com/urban-health-today/vertex-crispr-therapeutics-new-data-on-exa-cel-keeps-could-be-first-crispr-based-treatment/
   Google Scholar
• Southall J. Exa-cel may offer functional cure for beta-thalassemia, sickle cell disease, new data show: HemOnc today; 2022 [cited 2022 Oct 01]. Available from: https://www.healio.com/news/hematology-oncology/20220617/exacel-may-offer-functional-cure-for-betathalassemia-sickle-cell-disease-new-data-show
   Google Scholar
• Delea TE, Edelsberg J, Sofrygin O, et al. Consequences and costs of noncompliance with iron chelation therapy in patients with transfusion-dependent thalassemia: a literature review. Transfusion. 2007 Oct;47(10):1919–1929.
   PubMed Web of Science ®Google Scholar
• Locke M, Reddy PS, Badawy SM. Adherence to Iron Chelation therapy among adults with thalassemia: a systematic review. Hemoglobin. 2022 Aug;5:1–13.
   Google Scholar
• Drug approval package: deferoxamine mesylate injection: u.S. Food and Drug Administration; 2006 cited 2022 Aug 21]. Available from 2022 Aug 21: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/076019_s000_DeferoxamineTOC.cfm
   Google Scholar
• Neufeld EJ. Oral chelators deferasirox and deferiprone for transfusional iron overload in thalassemia major: new data, new questions. Blood. 2006 May 1; 107(9):3436–3441.
   PubMed Web of Science ®Google Scholar
• Saliba A, Taher A. Iron overload in transfusion-dependent thalassemia. Hematology. 2015 Jun;20(5):311–312.
   PubMed Web of Science ®Google Scholar
• Shashaty G, Frankewich R, Chakraborti T, et al. Deferasirox for the treatment of chronic iron overload in transfusional hemosiderosis. Oncology (Williston Park). Oncology (Williston Park, N.Y.). 2006 Dec;20(14):1799–1806. 1811; discussion 1811-13, 1817.
   PubMed Web of Science ®Google Scholar
• Badawy SM, Kattamis A, Ezzat H, et al. The safety and acceptability of twice-daily deferiprone for transfusional iron overload: a multicentre, open-label, phase 2 study. Br J Haematol. 2022 Apr;197(1):e12–e15.
   PubMed Web of Science ®Google Scholar
• Flora SJ, Pachauri V. Chelation in metal intoxication. Int J Environ Res Public Health. 2010 Jul;7(7):2745–2788.
   PubMed Web of Science ®Google Scholar
• Fradette C, Pichette V, Sicard E, et al. Effects of renal impairment on the pharmacokinetics of orally administered deferiprone. Br J Clin Pharmacol. 2016 Oct;82(4):994–1001.
   PubMed Web of Science ®Google Scholar
• Choudhry VP, Pati HP, Saxena A, et al. Deferiprone, efficacy and safety. Indian J Pediatr. 2004 Mar;71(3):213–216.
   PubMedGoogle Scholar
• Taher A, Chamoun FM, Koussa S, et al. Efficacy and side effects of deferiprone (L1) in thalassemia patients not compliant with desferrioxamine. Acta Haematol. 1999;101(4):173–177.
   PubMed Web of Science ®Google Scholar
• Olivieri NF, Koren G, Hermann C, et al. Comparison of oral iron chelator L1 and desferrioxamine in iron-loaded patients. Lancet. [1990 Nov 24];336(8726):1275–1279.
   PubMed Web of Science ®Google Scholar
• Galanello R. Deferiprone in the treatment of transfusion-dependent thalassemia: a review and perspective. Ther Clin Risk Manag. 2007 Oct;3(5):795–805.
   PubMedGoogle Scholar
• al-Refaie Fn, Wonke B, Hoffbrand AV, et al. Efficacy and possible adverse effects of the oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4-one (L1) in thalassemia major. Blood. [1992 Aug 1];80(3):593–599.
   PubMed Web of Science ®Google Scholar
• Agarwal MB, Gupte SS, Vasandani D, et al. Efficacy and safety of 1-2, dimethyl-3-hydroxypyrid-4-one (L1) as an oral iron chelator in patients of beta thalassaemia major with iron overload. J Assoc Physicians India. 1991 Sep;39(9):669–672.
   PubMedGoogle Scholar
• Kolnagou A, Kontoghiorghes GJ. Effective combination therapy of deferiprone and deferoxamine for the rapid clearance of excess cardiac IRON and the prevention of heart disease in thalassemia. The protocol of the International committee on oral chelators. Hemoglobin. 2006;30(2):239–249.
   PubMed Web of Science ®Google Scholar
• Pepe A, Lombardi M, Positano V, et al. Evaluation of the efficacy of oral deferiprone in beta-thalassemia major by multislice multiecho T2*. Eur J Haematol. 2006 Mar;76(3):183–192.
   PubMed Web of Science ®Google Scholar
• Maggio A, Kattamis A, Felisi M, et al. Evaluation of the efficacy and safety of deferiprone compared with deferasirox in paediatric patients with transfusion-dependent haemoglobinopathies (DEEP-2): a multicentre, randomised, open-label, non-inferiority, phase 3 trial. Lancet Haematol. 2020 Jun;7(6):e469–e478.
   PubMed Web of Science ®Google Scholar
• Farmaki K, Tzoumari I, Pappa C. Oral chelators in transfusion-dependent thalassemia major patients may prevent or reverse iron overload complications. Blood Cells Mol Dis. 2011 Jun 15;47(1):33–40.
   PubMed Web of Science ®Google Scholar
• Drakonaki EE, Maris TG, Maragaki S, et al. Deferoxamine versus combined therapy for chelating liver, spleen and bone marrow iron in beta-thalassemic patients: a quantitative magnetic resonance imaging study. Hemoglobin. 2010;34(1):95–106.
   PubMed Web of Science ®Google Scholar
• Farmaki K, Tzoumari I, Pappa C, et al. Normalisation of total body iron load with very intensive combined chelation reverses cardiac and endocrine complications of thalassaemia major. Br J Haematol. 2010 Feb;148(3):466–475.
   PubMed Web of Science ®Google Scholar
• Galanello R, Kattamis A, Piga A, et al. A prospective randomized controlled trial on the safety and efficacy of alternating deferoxamine and deferiprone in the treatment of iron overload in patients with thalassemia. Haematologica. 2006 Sep;91(9):1241–1243.
   PubMed Web of Science ®Google Scholar
• Kattamis A, Ladis V, Berdousi H, et al. Iron chelation treatment with combined therapy with deferiprone and deferioxamine: a 12-month trial. Blood Cells Mol Dis. 2006 Jan-Feb;36(1):21–25.
   PubMed Web of Science ®Google Scholar
• Athanassiou-Metaxa M, Kousi A, Hatzipantelis ES, et al. Combined chelation therapy with deferiprone and desferrioxamine in iron overloaded beta-thalassemia patients. Haematologica. 2004 Apr;89(4):ELT07.
   PubMedGoogle Scholar
• Kattamis A, Kassou C, Berdousi H, et al. Combined therapy with desferrioxamine and deferiprone in thalassemic patients: effect on urinary iron excretion. Haematologica. 2003 Dec;88(12):1423–1425.
   PubMed Web of Science ®Google Scholar
• Vitrano A, Ruffo GB, Pepe A, et al. Long-term sequential deferiprone and deferasirox therapy in transfusion-dependent thalassaemia patients: a prospective clinical trial. Br J Haematol. 2019 Sep;186(6):e209–e211.
   PubMed Web of Science ®Google Scholar
• Bellanti F, Del Vecchio GC, Putti MC, et al. Population pharmacokinetics and dosing recommendations for the use of deferiprone in children younger than 6 years. Br J Clin Pharmacol. 2017 Mar;83(3):593–602.
   PubMed Web of Science ®Google Scholar
• Cassinerio E, Roghi A, Pedrotti P, et al. Cardiac iron removal and functional cardiac improvement by different iron chelation regimens in thalassemia major patients. Ann Hematol. 2012 Sep;91(9):1443–1449.
   PubMed Web of Science ®Google Scholar
• Maggio A, Vitrano A, Lucania G, et al. Long-term use of deferiprone significantly enhances left-ventricular ejection function in thalassemia major patients. Am J Hematol. 2012 Jul;87(7):732–733.
   PubMed Web of Science ®Google Scholar
• Pantalone GR, Maggio A, Vitrano A, et al. Sequential alternating deferiprone and deferoxamine treatment compared to deferiprone monotherapy: main findings and clinical follow-up of a large multicenter randomized clinical trial in -thalassemia major patients. Hemoglobin. 2011;35(3):206–216.
   PubMed Web of Science ®Google Scholar
• Maggio A, Vitrano A, Capra M, et al. Long-term sequential deferiprone-deferoxamine versus deferiprone alone for thalassaemia major patients: a randomized clinical trial. Br J Haematol. 2009 Apr;145(2):245–254.
   PubMed Web of Science ®Google Scholar
• Maggio A, Vitrano A, Capra M, et al. Improving survival with deferiprone treatment in patients with thalassemia major: a prospective multicenter randomised clinical trial under the auspices of the Italian Society for Thalassemia and Hemoglobinopathies. Blood Cells Mol Dis. 2009 May-Jun;42(3):247–251.
   PubMed Web of Science ®Google Scholar
• Elalfy MS, Adly AM, Wali Y, et al. Efficacy and safety of a novel combination of two oral chelators deferasirox/deferiprone over deferoxamine/deferiprone in severely iron overloaded young beta thalassemia major patients. Eur J Haematol. 2015 Nov;95(5):411–420.
   PubMed Web of Science ®Google Scholar
• El-Beshlawy A, Manz C, Naja M, et al. Iron chelation in thalassemia: combined or monotherapy? The Egyptian experience. Ann Hematol. 2008 Jul;87(7):545–550.
   PubMed Web of Science ®Google Scholar
• Abdelrazik N. Pattern of iron chelation therapy in Egyptian beta thalassemic patients: mansoura University Children’s Hospital experience. Hematology. 2007 Dec;12(6):577–585.
   PubMed Web of Science ®Google Scholar
• Kwiatkowski JL, Hamdy M, El-Beshlawy A, et al. Deferiprone vs deferoxamine for transfusional iron overload in SCD and other anemias: a randomized, open-label noninferiority study. Blood Adv. [2022 Feb 22];6(4):1243–1254.
   PubMed Web of Science ®Google Scholar
• Loebstein R, Dalal I, Nisbet-Brown E, et al. Immune function in patients with beta thalassaemia receiving the orally active iron-chelating agent deferiprone. Br J Haematol. 1997 Sep;98(3):597–600.
   PubMed Web of Science ®Google Scholar
• Olivieri NF, Matsui D, Liu PP, et al. Oral iron chelation with 1,2-dimethyl-3-hydroxypyrid-4-one (L1) in iron loaded thalassemia patients. Bone Marrow Transplant. 1993;12 Suppl 1:9–11.
   PubMed Web of Science ®Google Scholar
• Olivieri NF, Koren G, St Louis P, et al. Studies of the oral chelator 1,2-dimethyl-3-hydroxypyrid-4-one in thalassemia patients. Semin Hematol. 1990 Apr;27(2):101–104.
   PubMed Web of Science ®Google Scholar
• Hammond J, Thompson AA, Fogel MA, et al. Combination oral chelation in adult patients with transfusion-dependent thalassemia and high iron burden. J Pediatr Hematol Oncol. 2019 Jan;41(1):e47–e50.
   PubMed Web of Science ®Google Scholar
• Songdej D, Sirachainan N, Wongwerawattanakoon P, et al. Combined chelation therapy with daily oral deferiprone and twice-weekly subcutaneous infusion of desferrioxamine in children with beta-thalassemia: 3-year experience. Acta Haematol. 2015;133(2):226–236.
   PubMed Web of Science ®Google Scholar
• Porter JB, Wood J, Olivieri N, et al. Treatment of heart failure in adults with thalassemia major: response in patients randomised to deferoxamine with or without deferiprone. J Cardiovasc Magn Reson. [2013 May 20];15(1):38.
   PubMedGoogle Scholar
• Mirbehbahani N, Jahazi A, Rahim Abad HH. The effect of combined therapy with deferoxamine and deferiprone on serum ferritin level of beta-thalassemic patients. Hematology. 2012 May;17(3):183–186.
   PubMed Web of Science ®Google Scholar
• Kolnagou A, Kleanthous M, Kontoghiorghes GJ. Efficacy, compliance and toxicity factors are affecting the rate of normalization of body iron stores in thalassemia patients using the deferiprone and deferoxamine combination therapy. Hemoglobin. 2011;35(3):186–198.
   PubMed Web of Science ®Google Scholar
• Zareifar S, Jabbari A, Cohan N, et al. Efficacy of combined desferrioxamine and deferiprone versus single desferrioxamine therapy in patients with major thalassemia. Arch Iran Med. 2009 Sep;12(5):488–491.
   PubMed Web of Science ®Google Scholar
• Tanner MA, Galanello R, Dessi C, et al. Combined chelation therapy in thalassemia major for the treatment of severe myocardial siderosis with left ventricular dysfunction. J Cardiovasc Magn Reson. [2008 Feb 25];10(1):12.
   PubMedGoogle Scholar
• Tanner MA, Galanello R, Dessi C, et al. A randomized, placebo-controlled, double-blind trial of the effect of combined therapy with deferoxamine and deferiprone on myocardial iron in thalassemia major using cardiovascular magnetic resonance. Circulation. [2007 Apr 10];115(14):1876–1884.
   PubMed Web of Science ®Google Scholar
• Daar S, Pathare AV. Combined therapy with desferrioxamine and deferiprone in beta thalassemia major patients with transfusional iron overload. Ann Hematol. 2006 May;85(5):315–319.
   PubMed Web of Science ®Google Scholar
• Mourad FH, Hoffbrand AV, Sheikh-Taha M, et al. Comparison between desferrioxamine and combined therapy with desferrioxamine and deferiprone in iron overloaded thalassaemia patients. Br J Haematol. 2003 Apr;121(1):187–189.
   PubMed Web of Science ®Google Scholar
• Aydinok Y, Ulger Z, Nart D, et al. A randomized controlled 1-year study of daily deferiprone plus twice weekly desferrioxamine compared with daily deferiprone monotherapy in patients with thalassemia major. Haematologica. 2007 Dec;92(12):1599–1606.
   PubMed Web of Science ®Google Scholar
• Bordbar M, Haghpanah S, Zekavat OR, et al. Effect of different iron chelation regimens on bone mass in transfusion-dependent thalassemia patients. Expert Rev Hematol. 2019 Nov;12(11):997–1003.
   PubMed Web of Science ®Google Scholar
• Ha SY, Chik KW, Ling SC, et al. A randomized controlled study evaluating the safety and efficacy of deferiprone treatment in thalassemia major patients from Hong Kong. Hemoglobin. 2006;30(2):263–274.
   PubMed Web of Science ®Google Scholar
• Ha SY, Mok AS, Chu WC, et al. Intermediate-term evaluation of a practical chelation protocol based on stratification of thalassemic patients by serum ferritin and magnetic resonance imaging cardiac t2*. Hemoglobin. 2011;35(3):199–205.
   PubMed Web of Science ®Google Scholar
• Kolnagou A, Kleanthous M, Kontoghiorghes GJ. Reduction of body iron stores to normal range levels in thalassaemia by using a deferiprone/deferoxamine combination and their maintenance thereafter by deferiprone monotherapy. Eur J Haematol. 2010 Nov;85(5):430–438.
   PubMed Web of Science ®Google Scholar
• Lin CH, Chen X, Wu CC, et al. Therapeutic mechanism of combined oral chelation therapy to maximize efficacy of iron removal in transfusion-dependent thalassemia major - a pilot study. Expert Rev Hematol. 2019 Apr;12(4):265–272.
   PubMed Web of Science ®Google Scholar
• Peng CT, Wu KH, Wu SF, et al. Deferiprone or deferoxamine vs. combination therapy in patients with beta-thalassemia major: a case study in Taiwan. Hemoglobin. 2006;30(1):125–130.
   PubMed Web of Science ®Google Scholar
• Gomber S, Saxena R, Madan N. Comparative efficacy of desferrioxamine, deferiprone and in combination on iron chelation in thalassemic children. Indian Pediatr. 2004 Jan;41(1):21–27.
   PubMedGoogle Scholar
• Balveer K, Pyar K, Wonke B. Combined oral and parenteral iron chelation in beta thalassaemia major. Med J Malaysia. 2000 Dec;55(4):493–497.
   PubMedGoogle Scholar
• Wonke B, Wright C, Hoffbrand AV. Combined therapy with deferiprone and desferrioxamine. Br J Haematol. 1998 Nov;103(2):361–364.
   PubMed Web of Science ®Google Scholar
• Ceci A, Baiardi P, Felisi M, et al. The safety and effectiveness of deferiprone in a large-scale, 3-year study in Italian patients. Br J Haematol. 2002 Jul;118(1):330–336.
   PubMed Web of Science ®Google Scholar
• Cohen AR, Galanello R, Piga A, et al. Safety and effectiveness of long-term therapy with the oral iron chelator deferiprone. Blood. [2003 Sep 1];102(5):1583–1587.
   PubMed Web of Science ®Google Scholar
• Maggio A, D’Amico G, Morabito A, et al. Deferiprone versus deferoxamine in patients with thalassemia major: a randomized clinical trial. Blood Cells Mol Dis. 2002 Mar-Apr;28(2):196–208.
   PubMed Web of Science ®Google Scholar
• Pati HP, Choudhry VP. Deferiprone (L1) associated neutropenia in beta thalassemia major: an Indian experience. Eur J Haematol. 1999 Oct;63(4):267–268.
   PubMed Web of Science ®Google Scholar
• Ferriprox FDA approval history: drugs.com; 2021 cited 2022 Aug 21]. Available from 2022 Aug 21: https://www.drugs.com/history/ferriprox.html
   Google Scholar
• Ferriprox: European Medicines Agency; 2009 [cited 2022 Sep 15]. Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/ferriprox
   Google Scholar
• Kontoghiorghes GJ, Kleanthous M, Kontoghiorghe CN. The history of deferiprone (L1) and the paradigm of the complete treatment of iron overload in thalassaemia. Mediterr J Hematol Infect Dis. 2020;12(1):e2020011.
   PubMedGoogle Scholar
• Chan JC, Chim CS, Ooi CG, et al. Use of the oral chelator deferiprone in the treatment of iron overload in patients with Hb H disease. Br J Haematol. 2006 Apr;133(2):198–205.
   PubMed Web of Science ®Google Scholar
• Kvarnstrom K, Westerholm A, Airaksinen M, et al. Factors contributing to medication adherence in patients with a chronic condition: a scoping review of qualitative research. Pharmaceutics. 2021 Jul 20;13(7):1–41.
   PubMed Web of Science ®Google Scholar
• El-Rachidi S, LaRochelle JM, Morgan JA. Pharmacists and pediatric medication adherence: bridging the gap. Hosp Pharm. 2017 Feb;52(2):124–131.
   PubMedGoogle Scholar
• Sedhai YR, Lamichhane A, Gupta VA. StatPearls. St. Petersburg, Florida: Treasure Island (FL); 2022.
   Google Scholar
• Calvaruso G, Vitrano A, Di Maggio R, et al. Deferiprone versus deferoxamine in sickle cell disease: results from a 5-year long-term Italian multi-center randomized clinical trial. Blood Cells Mol Dis. 2014 Dec;53(4):265–271.
   PubMed Web of Science ®Google Scholar
• Wanless IR, Sweeney G, Dhillon AP, et al. Lack of progressive hepatic fibrosis during long-term therapy with deferiprone in subjects with transfusion-dependent beta-thalassemia. Blood. [2002 Sep 1];100(5):1566–1569.
   PubMed Web of Science ®Google Scholar